NEW

Activ Surgical Announces FDA Clearance for ActivSight Intraoperative Imaging Module

Activ Surgical announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ActivSight Intraoperative Imaging Module for enhanced surgical visualization.

Metrex Surface Disinfectant Portfolio Secures EPA Approval

The U.S. Environmental Protection Agency (EPA) has approved all eight surface disinfectant products made by an infection prevention leader, Metrex, as effective against SARS-CoV-2, the novel coronavirus that causes COVID-19.

Olympus Supports Safety Actions Regarding Surgical Smoke

Olympus has announced its support of The Joint Commission’s recommended safety actions for managing the hazards of exposure to surgical smoke for health care staff in operating rooms.

Exofin Fusion Redesign Receives FDA Approval

Chemence Medical, a leader in medical cyanoacrylate devices and products, announced the U.S. Federal Drug Administration’s (FDA) 510(k) approval of the company’s redesigned exofin fusion skin closure system.

PURPLESUN Announces Strategic Partnership with APIC

PURPLESUN Announces Strategic Partnership with APICPURPLESUN INC. has announced a strategic partnership with the Association for Professionals in Infection Control and Epidemiology (APIC), the largest association for infection prevention and control (IPC) professionals.

APIC’s infection preventionist (IP) members work to prevent healthcare-associated infections (HAIs) in health care facilities. An estimated 633,000 hospitalized patients get HAIs each year and 72,000 die during their hospital stay, according to the Centers for Disease Control and Prevention.

The APIC Strategic Partner program establishes long-term relationships with industry partners united in the common goal of reducing the risk of infection. Partners play an important role in supporting many of the educational initiatives and services that make the APIC membership valuable to IPs on the frontlines in the fight against HAIs.

“PURPLESUN is pleased to partner with APIC to help prevent HAIs and expand education and resources for IPs,” said Luis F. Romo, CEO and founder of PurpleSun. “We share APIC’s patient safety mission and hope this partnership will help to strengthen APIC’s efforts to create a safer world through the prevention of infection.”

Scientific studies have shown that certified IPs are better prepared to interpret evidence and act as champions for key infection prevention practices. Hospitals with IPC programs led by certified IPs reported significantly lower rates of MRSA bloodstream infections.

“We are excited to welcome PURPLESUN as an APIC Strategic Partner,” said APIC CEO Katrina Crist, MBA, CAE. “Together, APIC and PURPLESUN will work together to improve healthcare outcomes and advanced education and certification for IPC professionals.”

PURPLESUN.COM is partnered with some of the largest health care systems in the U.S., and are on a mission to create the standard for light-based disinfection. PURPLESUN treats equipment and patient rooms in 90-second cycles using proprietary FMUV Shadowless Delivery technology with 99.99% germicidal performance, for the purposes of point of care disinfection. PurpleSun’s solutions allow for hospital-wide application, with one of the only products not requiring evacuation of the room during use. With the fastest cycle times, the products can integrate seamlessly with hospital operations with no impact on turn-over time.

As recently published in the American Journal of Infection Control – AJIC, a clinical trial demonstrated that PurpleSun FMUV was 96% effective in comparison to standard health care chemicals which were 38% effective for disinfection of hospital environments. As a data-driven organization, PurpleSun builds comprehensive and sustainable protocols for its customers that are expandable over time and can be monitored from the iOS app. Technology seminars are offered for continued education based on the latest research published and cited in AJIC and Association of periOperative Registered Nurses – AORN.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X